ARCHIVE

• Eyeforpharma Sales Force Effectiveness Japan 2007
  July 16, 2007

• Diovan Ranked No. 1 for 2 Months in a Row in Rep Track Survey
  July 16, 2007

• Blopress Ranks No. One 3 Times in 3 Years: Top-100 Drug Ranking
  July 16, 2007

• Nexavar to Become Standard Therapy for Hepatocellular Carcinoma
  July 16, 2007

• Nippon Kayaku Aims at Sales of \10 Billion with Generics
  July 16, 2007

• Takeda's MRs to Deal with All of Its Products: Mr Yamanaka
  July 16, 2007

• Nippon Shinyaku to Rebuild Pipeline with Niche Products: New President Maekawa
  July 16, 2007

• Adhesives Most Preferred Dosage Form of Narcotics for Cancer Pain
  July 16, 2007

• MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
  July 16, 2007

• Research to Prevent Progression of CKD to Dialysis to Start
  July 16, 2007

• Increases in Premiums Proposed by DPO Chairman
  July 9, 2007

• Psychoneurotic Drugs Account for 40% of Consultations on Drugs during Pregnancy
  July 9, 2007

• Eli Lilly Japan Files NDA for AD/HD Drug Atomoxetine
  July 9, 2007

• SURVEY／3 out of 4 Women Experience Hemorrhoids
  July 9, 2007

• REGULATORY NEWS IN BRIEF
  July 9, 2007

• seminar／Use of New Anticancer Agents Should Be Restricted to Specialists for Fixed Period
  July 9, 2007

• JGPMA to Discuss Full Membership Affiliation with the IGPA
  July 9, 2007

• Differences in Opinion over Generics Sharpen between JMA and Bill Payers
  July 9, 2007

• 27% Sales Growth for Philips Medical Systems in Japan in 2006: Dr Smit
  July 9, 2007

• seminar／Generic Substitution Essential to Further Promote Use of Generics: Dr Masuhara
  July 9, 2007

ページ

• « 先頭
• ‹ Prev
• …
• 330
• 331
• 332
• 333
• 334
• 335
• 336
• 337
• 338
• …
• Next ›
• 最終 »